Vector encoding human globin gene and use thereof in treatment of hemoglobinopathies

• US 7,541,179 B2
• Filed: 07/01/2002
• Issued: 06/02/2009
• Est. Priority Date: 06/29/2001
• Status: Expired due to Term

• Current Assignee: Sloan-Kettering Institute For Cancer Research (Memorial Sloan-Kettering Cancer Center)
• Original Assignee: Memorial Sloan-Kettering Cancer Center
• Inventors: May, Chad, Bertino, Joseph, Rivella, Stefano, Sadelain, Michel
• Primary Examiner(s): Marvich; Maria
• Application Number:
  US10/188,221
• Publication Number:
  US 20030022303A1
• Time in Patent Office: 2,528 Days
• Field of Search: 435/320.1
• US Class Current: 435/320.1
• CPC Class Codes: A61K 2035/124 the cells being hematopoietic, bone marrow derived or blood cells
• CPC Class Codes: A61K 48/00 Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
• CPC Class Codes: A61K 48/0066 Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
• CPC Class Codes: A61P 7/00 Drugs for disorders of the blood or the extracellular fluid
• CPC Class Codes: A61P 7/06 Antianaemics
• CPC Class Codes: C07K 14/805 Haemoglobins; Myoglobins
• CPC Class Codes: C12N 15/86 Viral vectors
• CPC Class Codes: C12N 2510/00 Genetically modified cells
• CPC Class Codes: C12N 2740/15043 viral genome or elements thereof as genetic vector

Abstract

Recombinant lentiviral vectors having a region encoding a functional β-globin gene; and large portions of the β-globin locus control regions which include DNase I hypersensitive sites HS2, HS3 and HS4 provides expression of β-globin when introduced into a mammal, for example a human, in vivo. Optionally, the vector further includes a region encoding a dihydrofolate reductase. The vector may be used in treatment of hemoglobinopathies, including β-thalessemia and sickle-cell disease. For example, hematopoietic progenitor or stem cells may be transformed ex vivo and then restored to the patient. Selection processes may be used to increase the percentage of transformed cells in the returned population. For example, a selection marker which makes transformed cells more drug resistant than un-transformed cells allows selection by treatment of the cells with the corresponding drug.

Claims

1. A recombinant vector comprising a nucleic acid encoding a functional globin operably linked to a 3.2-kb nucleotide fragment which consists essentially of three contiguous nucleotide fragments obtainable from a human β

-globin locus control region (LCR), the three fragments being a BstXI and SnaBI HS2-spanning nucleotide fragment of said LCR, a BamHI and HindIII HS3-spanning nucleotide fragment of said LCR and a BamHI and BanII HS4-spanning nucleotide fragment of said LCR, said vector providing expression of the globin in a mammal in vivo.

2. The vector of claim 1, further comprising a nucleic acid encoding a dihydrofolate reductase.

3. The vector of claim 2, further comprising a mouse PGK promoter to control the expression of the dihydrofolate reductase.

4. The vector of claim 3, wherein the dihydrofolate reductase is a human dihydrofolate reductase.

5. The vector of claim 4, wherein the human dihydrofolate reductase is a mutant dihydrofolate reductase having increased resistance to antifolates as compared to wild-type human dihydrofolate reductase and differing in amino acid sequence from wild-type human dihydrofolate reductase.

6. The vector of claim 5, wherein the mutant dihydrofolate reductase comprises a mutation at an amino acid corresponding to amino acid 22 of the wild-type sequence and a mutation at an amino acid corresponding to amino acid 31 of the wild type sequence.

7. The vector of claim 2, wherein the dihydrofolate reductase is a human dihydrofolate reductase.

8. The vector of claim 7, wherein the human dihydrofolate reductase is a mutant dihydrofolate reductase having increased resistance to antifolates as compared to wild-type human dihydrofolate reductase and differing in amino acid sequence from wild-type human dihydrofolate reductase.

9. The vector of claim 8, wherein the mutant dihydrofolate reductase comprises a mutation at an amino acid corresponding to amino acid 22 of the wild-type sequence and a mutation at an amino acid corresponding to amino acid 31 of the wild type sequence.

10. The vector of claim 1, wherein the functional globin is human β

-globin.

11. The vector of claim 10, further comprising a nucleic acid encoding a dihydrofolate reductase.

12. The vector of claim 11, further comprising a mouse PGK promoter to control the expression of the dihydrofolate reductase.

13. The vector of claim 12, wherein the dihydrofolate reductase is a human dihydrofolate reductase.

14. The vector of claim 13, wherein the human dihydrofolate reductase is a mutant dihydrofolate reductase having increased resistance to antifolates as compared to wild-type human dihydrofolate reductase and differing in amino acid sequence from wild-type human dihydrofolate reductase.

15. The vector of claim 14, wherein the mutant dihydrofolate reductase comprises a mutation at an amino acid corresponding to amino acid 22 of the wild-type sequence and a mutation at an amino acid corresponding to amino acid 31 of the wild type sequence.

16. The vector of claim 11, wherein the dihydrofolate reductase is a human dihydrofolate reductase.

17. The vector of claim 16, wherein the human dihydrofolate reductase is a mutant dihydrofolate reductase having increased resistance to antifolates as compared to wild-type human dihydrofolate reductase and differing in amino acid sequence from wild-type human dihydrofolate reductase.

18. The vector of claim 17, wherein the mutant dihydrofolate reductase comprises a mutation at an amino acid corresponding to amino acid 22 of the wild-type sequence and a mutation at an amino acid corresponding to amino acid 31 of the wild type sequence.

19. The vector of claim 1, wherein the functional globin is a β

-globin.

20. The vector of claim 1, wherein the functional globin is a γ

-globin.

21. The vector of claim 1, wherein the functional globin is an α

-globin.

22. The vector of claim 1, wherein the vector is a lentiviral vector.

23. A recombinant vector comprising a nucleic acid encoding a functional globin operably linked to a 3.2-kb nucleotide fragment which consists essentially of three nucleotide fragments obtainable from a human β

-globin LCR, the three fragments being a BstXI and SnaBI, HS2-spanning nucleotide fragment of said LCR, a BamHI and HindIII, HS3-spanning nucleotide fragment of said LCR, and a BamHI and BanII, HS4-spanning nucleotide fragment of said LCR, wherein the HS3-spanning nucleotide fragment and the HS4-spanning nucleotide fragment are adjacent to each other and the vector further comprises 2 GATA-1 binding sites at the junction between the HS3-spanning and HS4-spanning nucleotide fragments, said vector providing expression of the globin in a mammal in vivo.

24. The vector of claim 23, wherein the vector is pTNS9.